SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    O'Connor AM, Fiset V, Rostom A, et al. Systematic review of approaches to support people's decision making about health treatments or screening. Cochrane Collaboration Review. 1999.
  • 2
    Spunt BS, Deyo RA, Taylor VM, Leek KM, Goldberg HI, Mulley AG. An interactive videodisc program for low back pain patients. Health Educ Res. 1996;11:535 41.
  • 3
    O'Connor AM, Tugwell P, Wells G, et al. Randomized trial of a portable, self-administered decision aid for post-menopausal women considering long-term preventive hormone therapy. Med Decis Making. 1998;18:295 303.
  • 4
    Levine MN, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992; 117:53 8.
  • 5
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983 8.
  • 6
    Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.
  • 7
    The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Atrial Fibrillation Investigators. Arch Intern Med. 1997;157:1237 40.
  • 8
    Hart RG. Benavente O. McBride R. Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492 501.
  • 9
    Segal JB, McNamara RL, Miller MR, et al. Prevention of thromboembolism in atrial fibrillation. J Gen Intern Med. 2000;15:56 67.
  • 10
    Chang HJ, Bell JR, Deroo DB, Kirk JW, Wasson JH, Dartmouth Primary Care COOP Project. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med. 1990;150:83 6.
  • 11
    Dow L & Bertagne B. Anticoagulation in patients with atrial fibrillation. Underuse of warfarin is multifactorial. BMJ. 1993;307:1492 3.
  • 12
    Brass LM, Krumholz HM, Scinto JD, Mathur D, Radford M. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med. 1998;158:2093 100.
  • 13
    Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991;51: 1950 3.
  • 14
    McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995; 155:277 81.
  • 15
    O'Connor AM, Tugwell P, Wells GA, et al. A decision aid for women considering hormone replacement therapy after menopause: decision support framework and evaluation. Patient Educ Couns. 1998;33:267 79.
  • 16
    O'Connor AM, Drake ER, Fiset V, Graham ID, Laupacis A, Tugwell P. The Ottawa patient decision aids. Eff Clin Prac. 1999;2:163 70.
  • 17
    Morocoutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke. 1997;28:1015 21.
  • 18
    Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579S 89S.
  • 19
    Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;24:970 9.
  • 20
    Beyth RJ & Landefeld CS. Outcomes of warfarin therapy: lessons from the real world. Mayo Clin Proc. 1995;70:806 8.
  • 21
    Landefeld CS & Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Amer J Med. 1994;95:315 28.
  • 22
    Van Der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993;153:1557 62.
  • 23
    Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulation therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70:725 33.
  • 24
    Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423 42.
  • 25
    Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827 30.
  • 26
    Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmac. 1993;35:219 26.
  • 27
    Hart RG & Harrison MJG. Aspirin wars. The optimal dose of aspirin to prevent stroke. Stroke. 1996;27:585 7.
  • 28
    Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialist's Collaboration. BMJ. 1994;308:81 106.
  • 29
    Blackshear JL, Kopecky SL, Litin SC, Safford RE, Hammill SC. Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc. 1996; 71:150 60.
  • 30
    Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med. 1996;156:409 16.
  • 31
    O'Connor A, Tugwell P, Wells G. Testing a portable, self-administered decision aid for postmenopausal women considering long-term hormone replacement therapy to prevent osteoporosis and heart disease. Med Decis Making. 1994;14:438. Abstract.
  • 32
    Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med. 1993;153:1557 62.
  • 33
    Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation. A randomized controlled trial. JAMA. 1999;282:737 43.
  • 34
    Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF II Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998;279:1273 7.
  • 35
    O'Connor AM, Rostom A, Fiset V, et al. Decision aids for patients facing health treatment of screening decisions: systematic review. BMJ. 1999;319:731 4.
  • 36
    Barry MJ, Cherkin DC, Chang Y, Fowler FJ, Skates S. A randomized trial of a multimedia shared decision-making program for men facing a treatment decision for benign prostatic hypertrophy. Dis Manag Clin Outcomes. 1997;1:5 14.
  • 37
    Morgan MW. A Randomized Trial of the Ischemic Heart Disease Shared Decision Making Program: An Evaluation of a Decision Aid. Master's thesis. Toronto, Ontario, Canada: University of Toronto; 1997.
  • 38
    Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677 85.